Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with...
-
Upload
betty-boyd -
Category
Documents
-
view
234 -
download
4
Transcript of Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with...
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
PD-1/ PD-L1 pathway in suppressing anti-tumor immunity
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Slide 3
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Nivolumab <br />(ONO4538/BMS936558)
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Study design: Investigator initiated, 2 cohorts Phase II
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Key inclusion criteria
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Study schedule
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Demographics
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Adverse events: Regardless of causality <br /> (>=4 patients)
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Slide 10
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Serious adverse events<br />(Treatment-related)
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Clinical Effect : Best Overall Response
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
A Responder with Serous adenoca : <br />Nivolumab 3mg/kg
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
A Responder with Clear cell carcinoma :<br />Nivolumab 3mg/kg
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Best overall responses in all patients
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Best overall responses in all patients in 2 cohorts
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Summary
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Conclusions
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Acknowledgements
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Research group
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Slide 21
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Clinical Effect : Response Duration
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Best overall responses in all patients
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
Slide 24
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting